LONDON, March 26, 2014 /PRNewswire/ --
On Tuesday, March 25, 2014, the
NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones
Industrial Average advanced 0.56% to 16,367.88, and the S&P 500
closed at 1,865.62, up 0.44%. The gains were broad based as nine
out of 10 sectors ended the session in positive. The S&P 500
Health Care Sector Index finished the day at 671.69, up 0.83%,
while the same has fallen by 1.64% in the last one month.
Investor-Edge has initiated coverage on the following equities:
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum
Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).
Free technical research on BCRX, SPPI, BMRN, and VRTX can be
downloaded upon signing up at:
http://www.investor-edge.com/504-register
Shares in BioCryst Pharmaceuticals Inc. closed at $10.02 on Tuesday, which is 1.38% lower than the
previous day's closing price of $10.16. A total of 0.39 million shares were
traded as compared with three months average volume of 1.26 million
shares. The company's shares oscillated between $9.89 and $10.52 during the trading session.
Shares in BioCryst Pharmaceuticals Inc. have declined 21.90% in the
last one month, while the same has rallied 34.32% in the previous
three months and 31.84% on YTD basis. The stock is trading above
its 200-day moving average. BioCryst Pharmaceuticals Inc.'s 50-day
moving average of $10.92 is above the
200-day moving average of $6.78.
Furthermore, the stock is trading at a Relative Strength Index
(RSI) of 41.60. Sign up today to read free research on BCRX at:
http://www.investor-edge.com/504-BCRX-26Mar2014.pdf
Spectrum Pharmaceuticals Inc.'s stock witnessed trading of 0.87
million shares on Tuesday, which is below the three months average
volume of 0.89 million shares. The stock ended the day at
$7.72, down 0.77%, after trading
between $7.56 and $7.91 during the
session. Shares in Spectrum Pharmaceuticals Inc. have lost 10.44%
in the last one month and 12.77% on YTD basis. The stock is trading
below its 50-day and 200-day moving averages. Spectrum
Pharmaceuticals Inc.'s 50-day moving average of $8.52 is above the 200-day moving average of
$8.47. Additionally, shares of the
company are trading at an RSI of 39.62. Sign up today to read free
research on SPPI at:
http://www.investor-edge.com/504-SPPI-26Mar2014.pdf
On Tuesday, BioMarin Pharmaceutical Inc.'s stock declined 2.25%
finishing the session at $72.05. The
stock recorded a trading volume of 3.21 million shares which is
above the three months average volume of 1.29 million shares. The
company's shares fluctuated between $68.91
and $74.51 during the session. Shares in BioMarin
Pharmaceutical Inc. have fallen by 12.33% in the last one month,
while the same has gained 4.12% in the previous three months and
2.42% on YTD basis. The stock is trading above its 200-day moving
average. BioMarin Pharmaceutical Inc.'s 50-day moving average of
$74.72 is above the 200-day moving
average of $68.28. Moreover, shares
of the company are trading at an RSI of 40.29. Sign up today to
read free research on BMRN at:
http://www.investor-edge.com/504-BMRN-26Mar2014.pdf
Vertex Pharmaceuticals Inc.'s stock recorded a trading volume of
1.41 million shares, as compared with a three month average volume
of 1.50 million shares. The stock ended Tuesday's session at
$71.90, down 0.75% after vacillating
between $70.31 and $73.92. Shares in Vertex Pharmaceuticals Inc.
have lost 15.03% in the last one month and 3.23% on YTD basis. The
stock is trading below its 50-day and 200-day moving averages.
Vertex Pharmaceuticals Inc.'s 50-day moving average of $80.61 is above the 200-day moving average of
$76.52. Further, the company's shares
are trading at a PE ratio of 366.23 and at an RSI of 29.70. Sign up
today to read free research on VRTX at:
http://www.investor-edge.com/504-VRTX-26Mar2014.pdf
EDITOR'S NOTES:
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge